• Cytochroma Ltd., of Markham, Ontario, reported data from a 78-subject Phase IIb trial showing that CTAP101 capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage III or Stage IV chronic kidney disease and vitamin D insufficiency.